2. ADMINISTRATION OF THE COLLABORATION 21 2.1 Joint Steering Committee 21 2.2 Joint Development Committee 23 2.3 Alliance Managers 26 2.4 Joint Finance Committee 26 2.5 Joint Marketing Committee 28 3. RESEARCH PROGRAM 29 3.1 Objectives of the Research...Collaborative Development and License Agreement • November 3rd, 2006 • Immunogen Inc • Pharmaceutical preparations • New York
This COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into as of July 7, 2006 (the “Effective Date”), by and between ImmunoGen, Inc., a Massachusetts corporation with its principal place of business at 128 Sidney Street, Cambridge, Massachusetts, USA 02139 (“ImmunoGen”) and Biotest AG, a corporation organized under the laws of Germany having an address of Landsteinerstraße 5, D-63303 Dreieich, Germany (“Biotest”). Each of Biotest and ImmunoGen is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 TO THE COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • November 3rd, 2006 • Immunogen Inc • Pharmaceutical preparations
This Amendment No. 1 to the Collaboration and License Agreement (this “Amendment”) is dated as of August 31, 2006 (the “Amendment Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation with a principal office at 128 Sidney Street, Cambridge, Massachusetts 02139 (“ImmunoGen”), and sanofi-aventis U. S. LLC, a Delaware limited liability company with a offices at 1041 Rt. 202-206, Bridgewater, NJ 08807 (“sanofi-aventis”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Collaboration and License Agreement (the “Agreement”) dated as of July 30, 2003 (the “Agreement Effective Date”) by and between ImmunoGen and Aventis Pharmaceuticals, Inc. (“Aventis”).
AMENDMENT NO. 1 TO COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENTAnd License Agreement • November 3rd, 2006 • Immunogen Inc • Pharmaceutical preparations
This Amendment No. 1 (this "Amendment No. 1") to the Collaborative Development and License Agreement (this “Agreement”) entered into as of July 7, 2006 (the "Agreement Effective Date") by and between ImmunoGen, Inc., a Massachusetts corporation with its principal place of business at 128 Sidney Street, Cambridge, Massachusetts, USA 02139 (“ImmunoGen”) and Biotest AG, a corporation organized under the laws of Germany having an address of Landsteinerstraße 5, D-63303 Dreieich, Germany (“Biotest”) is dated as of August 23, 2006 (the “Amendment Effective Date”).
